Key facts
- This page summarizes Nate Nguyen's Form 3 filing for Cullinan Oncology, Inc. (CGEM).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 02 Apr 2024, 20:50.
Nate Nguyen - 29 Mar 2024 Form 3 Insider Report for Cullinan Oncology, Inc. (CGEM)
- Reporting relationship
- Interim PAO and PFO
- Issuer ticker
- CGEM
- Reported as of
- 29 Mar 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jacquelyn Sumer, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Nate Nguyen filed Form 3 for Cullinan Oncology, Inc. (CGEM) on 02 Apr 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CGEM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,250
- Date
- 29 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
CGEM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,375
- Date
- 29 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
CGEM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,375
- Date
- 29 Mar 2024
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CGEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $48.39
- Footnotes
- F4
CGEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 62,500
- Exercise price
- $13.60
- Footnotes
- F5
CGEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,750
- Exercise price
- $11.34
- Footnotes
- F6
CGEM
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,750
- Exercise price
- $17.54
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.
Footnote F2
The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 17, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Footnote F3
The shares underlying the restricted stock unit vest over four years until the fourth anniversary of February 22, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Footnote F4
25% of the shares vested on January 25, 2022, and the remaining shares vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Footnote F5
The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.
Footnote F6
The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 17, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Footnote F7
The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 22, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
SEC remarks
Exhibit 24 - Power of Attorney